| Identification | Back Directory | [Name]
Emibetuzumab | [CAS]
1365287-97-3 | [Synonyms]
Emibetuzumab
Emibetuzumab (anti-MET)
Research Grade Emibetuzumab(DHC34201) |
| Hazard Information | Back Directory | [Description]
Emibetuzumab is a bivalent antibody that blocks HGF- and MET-receptor interaction,
leading to MET internalization and degradation. | [Clinical Use]
A phase I study determined a tolerable dose for emibetuzumab to be 700–2000 mg as a monotherapy and
in combination with erlotinib in NSCLC patients. It is currently being investigated in phase II in combination with erlotinib. |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18162686757 |
| Website: |
www.biolabreagent.com/ |
|